<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from Select
Therapeutics Inc. consolidated financial statements for the year ended June 30,
2000 and is qualified in its entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                            JUN-30-2000
<PERIOD-START>                               JUL-01-1999
<PERIOD-END>                                 JUN-30-2000
<CASH>                                         7,901,288
<SECURITIES>                                           0
<RECEIVABLES>                                     17,042
<ALLOWANCES>                                           0
<INVENTORY>                                       29,938
<CURRENT-ASSETS>                               8,004,784
<PP&E>                                           174,408
<DEPRECIATION>                                    65,468
<TOTAL-ASSETS>                                 8,113,724
<CURRENT-LIABILITIES>                            811,134
<BONDS>                                                0
                                  0
                                            0
<COMMON>                                           1,186
<OTHER-SE>                                     7,301,404
<TOTAL-LIABILITY-AND-EQUITY>                   8,113,724
<SALES>                                          187,632
<TOTAL-REVENUES>                                 293,702
<CGS>                                                  0
<TOTAL-COSTS>                                          0
<OTHER-EXPENSES>                               5,016,100
<LOSS-PROVISION>                                       0
<INTEREST-EXPENSE>                                     0
<INCOME-PRETAX>                               (4,722,398)
<INCOME-TAX>                                           0
<INCOME-CONTINUING>                           (4,722,398)
<DISCONTINUED>                                         0
<EXTRAORDINARY>                                        0
<CHANGES>                                              0
<NET-INCOME>                                  (4,722,398)
<EPS-BASIC>                                        (0.58)
<EPS-DILUTED>                                      (0.58)



</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission